I think this announcement has presented nothing more then a buying opportunity from impatient retail investors.
The FDA meeting was already scheduled in October of last year, but could not happen till January. It wasn't until this meeting took place that CYC could set a timeline for what needs to happen still.
I am actually glad that Cyclopharm is not rushing back with a quick FDA resubmission, but are making sure all their i's are dotted and all their t's are crossed.
Patience will be rewarded in this stock.
CYC Price at posting:
$1.56 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)